Epigenetic Regulation in Melanoma: Facts and Hopes

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cutaneous melanoma remains a lethal disease, particularly in advanced stages.
• Recent therapeutic advances have improved survival, but new approaches are essential.
• Epigenetic deregulation, involving DNA methylation and chromatin remodeling, is implicated in cancer initiation, progression, and drug resistance.

Purpose of the Study:

• To review the current understanding of epigenetics in melanoma.
• To identify established and potential epigenetic targets for therapeutic intervention.
• To explore the use of epigenetic drugs in advanced melanoma treatment.

Main Methods:

• Review of recent preclinical models and patient sample studies on melanoma epigenetics.
• Analysis of the role of epigenetics in melanomagenesis and drug resistance.
• Identification of potential therapeutic targets based on epigenetic alterations.

Main Results:

• Epigenetic alterations are involved in melanoma initiation, progression, and resistance to therapies like immune checkpoint inhibitors and MAPK inhibitors.
• Studies in preclinical models and patient samples highlight epigenetics' role throughout melanoma development.
• Specific epigenetic modifications and their regulatory mechanisms in melanoma are increasingly understood.

Conclusions:

• Epigenetics represents a promising area for novel therapeutic strategies in melanoma.
• Targeting epigenetic mechanisms, alone or in combination with other agents, may improve outcomes for advanced melanoma patients.
• Further research into epigenetic drug targets is warranted for clinical testing in melanoma.